Epiphany Biosciences, Inc.

Epiphany Biosciences, Inc. is a biotechnology firm focused on developing innovative therapeutic solutions to address unmet medical needs. The company utilizes advanced technologies to create breakthrough treatments and improve patient outcomes. Epiphany Biosciences, Inc.

is engaged in the development of novel therapeutic solutions. Founded in the early 2000s, the company is headquartered in San Francisco, US. In March 2007, Epiphany raised USD 36 mn in Series A financing led by Wexford Capital with participation from CDIB BioScience Venture Management, Windsor Bay Capital, and Global Trust Partners. The company has no known subsidiaries or major pivots in its business strategy since its inception.

Epiphany Biosciences, Inc. specializes in the discovery and development of innovative therapies aimed at addressing complex diseases. The company’s research focuses on harnessing cutting-edge scientific advancements to create effective treatment options that may enhance patient care and clinical outcomes. Epiphany Biosciences, Inc.

follows a model that generates revenue through the commercialization of its therapeutic products as they successfully advance through clinical trials and regulatory approvals. The company’s financial framework is designed to support ongoing research and product development efforts, ensuring the sustainability of its operations as it moves towards market entry. Epiphany Biosciences, Inc. aims to leverage its most recent Series A funding of USD 36 mn to accelerate the development of its therapeutic products.

The company is focused on expanding its research initiatives and is exploring new geographic markets for potential product launches. Specific release dates for upcoming products are not disclosed, but the firm plans to utilize its capital for enhancing research capabilities and pursuing collaborations that could facilitate entry into new markets.